Skip to main content
Press Release RSS Feed (opens in new window)

Press Releases

Press release year list 2020 2019 2018 2017 2016 2015 2014 2013
Trillium Therapeutics Appoints Michael Kamarck, Ph.D., to Its Board of Directors
September 18, 2020
Download PDF format download (opens in new window)
Trillium Closes US$150 Million Public Offering of Common Shares
September 16, 2020
Download PDF format download (opens in new window)
Trillium Announces Pricing of US$130 Million Public Offering of Common Shares
September 10, 2020
Download PDF format download (opens in new window)
Trillium Announces Proposed Public Offering of Common Shares
September 9, 2020
Download PDF format download (opens in new window)
Trillium Therapeutics Announces $25 Million Equity Investment From Pfizer Inc.
September 8, 2020
Download PDF format download (opens in new window)
Trillium Therapeutics Announces Updated Data From Its Ongoing TTI-622 and TTI-621 Dose Escalation Studies
September 8, 2020
Download PDF format download (opens in new window)
Trillium Therapeutics Reports Second Quarter 2020 Financial and Operating Results
August 12, 2020
Download PDF format download (opens in new window)
Trillium Therapeutics Provides Update On Phase 1 Study Of TTI-621 And Dose Escalation To 2.0 MG/KG Level
July 30, 2020
Download PDF format download (opens in new window)
Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders
July 6, 2020
Download PDF format download (opens in new window)
Trillium Therapeutics Provides Update on the Phase I Dose Escalation Study of Its CD47 Blocker TTI-622 at the ASCO20 Virtual Scientific Program
May 29, 2020
Download PDF format download (opens in new window)
Trillium Therapeutics Reports First Quarter 2020 Financial and Operating Results
May 15, 2020
Download PDF format download (opens in new window)
Trillium Therapeutics to Present Data on CD47 Blocker TTI-622 in Advanced Relapsed or Refractory Lymphoma at the ASCO20 Virtual Scientific Program
May 13, 2020
Download PDF format download (opens in new window)
Trillium Therapeutics Announces “At-The-Market” Equity Program
May 6, 2020
Download PDF format download (opens in new window)
Trillium Therapeutics Provides Business Update in Response to the Covid-19 Pandemic
April 8, 2020
Download PDF format download (opens in new window)
Trillium Therapeutics Reports Annual Financial and Operating Results
March 10, 2020
Download PDF format download (opens in new window)
Trillium Therapeutics Responds to Market Activity
February 28, 2020
Download PDF format download (opens in new window)
Trillium Therapeutics Announces Changes to Its Board of Directors
February 7, 2020
Download PDF format download (opens in new window)
Trillium Closes US$117 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares
January 29, 2020
Download PDF format download (opens in new window)
Trillium Announces Pricing of US$101,700,000 Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares
January 23, 2020
Download PDF format download (opens in new window)
Trillium Announces Proposed Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares
January 22, 2020
Download PDF format download (opens in new window)
Trillium Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
January 16, 2020
Download PDF format download (opens in new window)
Trillium Therapeutics Provides Update on Its TTI-621 and TTI-622 CD47 Programs
January 7, 2020
Download PDF format download (opens in new window)